Results 1 to 9 of 9

Thread: InVivo Therapeutics Announces Positive Motor Recovery Assessments in Two Patients

  1. #1
    Senior Member mj23's Avatar
    Join Date
    Sep 2005
    Location
    Chicago, IL
    Posts
    486

    InVivo Therapeutics Announces Positive Motor Recovery Assessments in Two Patients

    InVivo Therapeutics Announces Positive Motor Recovery Assessments in Two Patients in the INSPIRE Study of the Neuro-Spinal Scaffold?
    ? Continued Improvement from AIS B to AIS C for Two Patients with Early Conversions ?
    CAMBRIDGE, Mass. (June 28, 2017) ? InVivo Therapeutics Holdings Corp. (NVIV) today announced that two patients in the INSPIRE study of the Neuro-Spinal Scaffold have improved from sensory incomplete AIS B spinal cord injury (SCI) to motor incomplete AIS C SCI in their most recent INSPIRE assessments. These are the second and third patients in the INSPIRE study to have reached AIS C motor incomplete classification.
    One of these patients was enrolled in May 2016 and converted from complete AIS A SCI to incomplete AIS B SCI at the three-month exam in August 2016. At the 12-month visit, the patient regained motor function associated with the most sacral segments of the spinal cord and was assessed to be AIS C. Stuart Lee, M.D., is the Principal Investigator at Vidant Medical Center in Greenville, North Carolina, where this patient was implanted with the Neuro-Spinal Scaffold.
    Dr. Lee said, ?The patient?s continued improvement at the one year exam is encouraging. Return of sacral motor function may be related to improvements in bowel and bladder function that can have an appreciable impact on a patient?s quality of life. We look forward to monitoring this patient?s recovery and hope for continued progress.?
    The second patient was enrolled in June 2015 and converted from complete AIS A SCI to incomplete AIS B SCI at the one-month exam in July 2015. At the 24-month per protocol ISNCSCI exam (see About the ISNCSCI Exam below), the patient was assessed to be AIS C with the ability to contract two muscles of one leg. The motor function was not noted in a separate medical evaluation earlier in the day that did not include a full ISNCSCI exam. Domagoj Coric, M.D., of Carolina Neurosurgery and Spine Associates, and William Bockenek, M.D., of Carolinas Rehabilitation, are Co-principal Investigators at the site where this patient was implanted.
    Dr. Bockenek said, ?This patient moved from AIS A to AIS B shortly after the initial injury and implantation with the Neuro-Spinal Scaffold two years ago, and now is noted on the ISNCSCI exam to have moved to an AIS C based on trace movements in one leg. Though the clinical significance of this change is unknown at this time, we remain cautiously optimistic that there may be a possibility for additional changes.?
    InVivo CEO and Chairman Mark Perrin said, ?We are excited that these two patients have continued to progress beyond the period of early improvement. Three of the five patients with an AIS conversion in INSPIRE have demonstrated motor recovery and are now classified as AIS C conversions. Having assessments of motor improvements occurring one or two years post-implantation is uncommon and may be indicative of prolonged neural repair.?
    About the ISNCSCI Exam
    The International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) exam is a full neurological exam designed to characterize a patient?s SCI, including full motor and sensory testing. Based upon the findings of the ISNCSCI exam, an American Spinal Injury Association Impairment Scale (?AIS?) grade classification is determined. For more information, refer to the ISNCSCI exam worksheet at: http://asia-spinalinjury.org/wp-content/uploads/2016/02/International_Stds_Diagram_Worksheet.pdf
    About the Neuro-Spinal Scaffold? Implant
    Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural repair within and around the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in The INSPIRE Study for the treatment of patients with acute, complete (AIS A), thoracic traumatic spinal cord injury and a pilot study for acute, complete (AIS A), cervical (C5-T1) traumatic spinal cord injury.
    About InVivo Therapeutics
    InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children?s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company?s investigational Neuro-Spinal Scaffold received the 2015 Becker?s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
    C-5, 6 SCI. Took about 6 months to walk. Walking full time. Without any assistance since Nov. 2003 and will make a full recovery

  2. #2
    Senior Member
    Join Date
    Dec 2016
    Location
    Houston, Texas
    Posts
    181
    They need to start doing Chronic SCI!

  3. #3
    Senior Member
    Join Date
    Dec 2016
    Location
    Houston, Texas
    Posts
    181

    2017 InVivo Therapeutics ASM Recording




    https://www.youtube.com/watch?v=lndx...Dr0Fi-qKl6xpnA

  4. #4
    Senior Member
    Join Date
    Apr 2016
    Location
    Cincinnati, Ohio, USA
    Posts
    2,453
    Keep those muscles and nerves working folks. I don't know the frequency with which we should be doing FES/ESTIM...weekly?
    T3 complete since Sept 2015.

  5. #5
    Quote Originally Posted by Mize View Post
    Keep those muscles and nerves working folks. I don't know the frequency with which we should be doing FES/ESTIM...weekly?
    30 minutes per day, 3 times per week is the minimum frequency and duration for clinical benefits as reported in the literature for FES-cycling. Not sure about other modalities. Generally speaking, the more the better.

  6. #6
    Senior Member
    Join Date
    Jun 2011
    Location
    North Carolina
    Posts
    841
    I record at least a mile a night while sleeping from spasms, on the fitbit. Does that count? Haha

  7. #7
    Senior Member Tim C.'s Avatar
    Join Date
    Oct 2002
    Location
    New Jersey
    Posts
    2,058
    Blog Entries
    1
    ASIA B or less tests cannot be reliably duplicated, scientists know this.

  8. #8
    SOmeone was asking when Invivo will work on Chronics. The answer is once they have the acute product on the market (2018) so they can have sustainable revenue. Great news is that the trial is 85% complete and the results are good. Approval should come next year!

  9. #9
    Senior Member
    Join Date
    Dec 2016
    Location
    Houston, Texas
    Posts
    181
    Quote Originally Posted by BeInspired View Post
    SOmeone was asking when Invivo will work on Chronics. The answer is once they have the acute product on the market (2018) so they can have sustainable revenue. Great news is that the trial is 85% complete and the results are good. Approval should come next year!
    Thank you for this information!

Similar Threads

  1. Replies: 20
    Last Post: 01-31-2016, 03:01 AM
  2. Replies: 0
    Last Post: 12-02-2015, 02:25 PM
  3. Replies: 0
    Last Post: 06-24-2014, 07:59 AM
  4. Replies: 0
    Last Post: 06-08-2011, 11:06 AM
  5. Replies: 1
    Last Post: 03-12-2011, 01:20 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •